Biopharma Pulse - 3/21 - 3/25 Week in Review

As we near the end of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.

Table 1. BPIQ company weekly moves and YTD moves

Highlights for the week of 3/21 - 3/25

Biggest positive move

• $NEXI +96.3% Form 4 filing - Neximmune director acquired 30,000 shares

Biggest negative move

• $VLON -72.6% Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD.

Additional big moves

• $YMTX +78.6% Financial results

• $CRBP +66.7%

• $SPPI +47.8% Financial results

• $ASMB +22.4% Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022.

• $OBSV +8.1% ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain.

• $LBPS +5.8% 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma.

• $IMGN -19.0% ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting.

• $CNTB -37.6%

• $MEIP -64.6% MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA

• $ICVX -69.9% Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2. (data inconsistent)

Highlights for next week

• Companies with commercial products and quarterly financial reports

  • $KALA

  • $SCYX

  • $AGRX

  • $KMPH

• $AKBA PDUFA target action date

• $LPCN PDUFA target action date

See our Big Movers post to learn more about the remaining March Big Movers and Movers to Watch after subscribing. Learn more here.